
    
      15 treatment-naive CHC patients and 10 healthy controls were recruited. Patients were
      examined before DAAs therapy (0w) and at weeks 4 (4w) and weeks 12 (12w) of the therapy. The
      percentage of monocytes,NK cells of the peripheral blood were analyzed by flow cytometry.
      Serum cytokines IL-12, IL-18, CXCL10, CXCL11, sCD14 and sCD163 were measured by enzyme linked
      immunosorbent assay.
    
  